$ATAI
ATAI Life Sciences NV Stock $atai

$atai Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023009756 Filed on March 24, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$37.00K	$38.00K	$233.0K
YoY Change		-83.48%	-98.86%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$13.97M	$15.73M	$70.35M
YoY Change	-22.31%	-39.22%	-24.15%
% of Gross Profit
Research & Development	$19.28M	$21.88M	$74.31M
YoY Change	24.72%	68.51%	54.96%
% of Gross Profit
Depreciation & Amortization	$65.00K	$53.00K	$168.0K
YoY Change	8.33%	82.76%	257.45%
% of Gross Profit
Operating Expenses	$33.25M	$37.60M	$145.0M
YoY Change	-0.57%	-3.23%	-7.15%
Operating Profit	-$33.21M		-$144.8M
YoY Change	-0.68%		6.61%
Interest Expense	$622.0K	-$4.426M	$7.450M
YoY Change	-72.49%	21.06%	-317.9%
% of Operating Profit
Other Income/Expense, Net	$58.00K	$2.670M	$9.605M
YoY Change	-96.19%	959.52%	-1306.66%
Pretax Income	-$33.16M	-$39.32M	-$135.2M
YoY Change	3.87%	-19.06%	-1.04%
Income Tax	$200.0K	$6.002M	$6.229M
% Of Pretax Income
Net Earnings	-$33.14M	-$45.01M	-$152.4M
YoY Change	-10.13%	-49.36%	-9.19%
Net Earnings / Revenue	-89554.05%	-118450.0%	-65401.29%
Basic Earnings Per Share	-$0.21		-$0.98
Diluted Earnings Per Share	-$0.21	-$0.28	-$0.98
COMMON SHARES
Basic Shares Outstanding	166.0M	165.9M	155.7M
Diluted Shares Outstanding	155.8M		155.7M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$249.9M	$273.1M	$273.1M
YoY Change	-25.39%	-24.61%	-24.61%
Cash & Equivalents	$185.9M	$190.6M	$190.6M
Short-Term Investments	$64.00M	$82.50M	$82.50M
Other Short-Term Assets	$1.982M	$1.745M	$3.779M
YoY Change	42.69%	130.82%	-41.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$267.9M	$287.1M	$287.1M
YoY Change	-23.18%	-23.44%	-23.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.114M	$928.0K	$928.0K
YoY Change	525.84%	522.82%	522.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$5.846M	$0.00	$6.755M
YoY Change	-40.03%	-100.0%	-75.67%
Other Assets	$3.180M	$3.351M	$3.351M
YoY Change	-57.62%	-54.35%	-54.35%
Total Long-Term Assets	$12.78M	$18.30M	$18.30M
YoY Change	-63.42%	-53.19%	-53.19%
TOTAL ASSETS
Total Short-Term Assets	$267.9M	$287.1M	$287.1M
Total Long-Term Assets	$12.78M	$18.30M	$18.30M
Total Assets	$280.7M	$305.4M	$305.4M
YoY Change	-26.85%	-26.25%	-26.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.915M	$2.399M	$2.399M
YoY Change	36.07%	-60.04%	-60.04%
Accrued Expenses	$13.82M	$17.31M	$15.08M
YoY Change	-24.29%	16.7%	125.37%
Deferred Revenue
YoY Change
Short-Term Debt	$64.00M	$82.50M	$0.00
YoY Change	-69.65%
Long-Term Debt Due	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$19.95M	$19.90M	$19.90M
YoY Change	-9.68%	-4.96%	-4.96%
LONG-TERM LIABILITIES
Long-Term Debt	$15.21M	$15.12M	$15.12M
YoY Change	1997.24%	1934.59%	1934.59%
Other Long-Term Liabilities	$2.816M	$3.708M	$4.661M
YoY Change	-31.75%	-9.49%	-28.61%
Total Long-Term Liabilities	$2.816M	$3.708M	$19.78M
YoY Change	-31.75%	-9.49%	171.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.95M	$19.90M	$19.90M
Total Long-Term Liabilities	$2.816M	$3.708M	$19.78M
Total Liabilities	$40.08M	$39.68M	$44.70M
YoY Change	36.43%	40.66%	19.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$543.8M	-$510.2M
YoY Change	37.78%	42.59%
Common Stock	$18.57M	$18.56M
YoY Change	3.13%	3.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$236.8M	$260.7M	$260.7M
YoY Change
Total Liabilities & Shareholders Equity	$280.7M	$305.4M	$305.4M
YoY Change	-26.85%	-26.25%	-26.25%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$33.14M	-$45.01M	-$152.4M
YoY Change	-10.13%	-49.36%	-9.19%
Depreciation, Depletion And Amortization	$65.00K	$53.00K	$168.0K
YoY Change	8.33%	82.76%	257.45%
Cash From Operating Activities	-$21.11M	-$30.50M	-$104.5M
YoY Change	-11.99%	48.74%	65.18%
INVESTING ACTIVITIES
Capital Expenditures	$280.0K	$223.0K	$773.0K
YoY Change	400.0%	-162.46%	346.82%
Acquisitions
YoY Change
Other Investing Activities	$16.46M	$80.27M	-$85.82M
YoY Change		-266.28%
Cash From Investing Activities	$16.02M	$80.05M	-$86.85M
YoY Change	-107.46%	-264.6%	6.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	206.0K	-922.0K	20.79M
YoY Change	56.06%	-153.51%	-94.93%
NET CHANGE
Cash From Operating Activities	-21.11M	-30.50M	-104.5M
Cash From Investing Activities	16.02M	80.05M	-86.85M
Cash From Financing Activities	206.0K	-922.0K	20.79M
Net Change In Cash	-4.728M	48.63M	-171.7M
YoY Change	-98.02%	-172.12%	-164.77%
FREE CASH FLOW
Cash From Operating Activities	-$21.11M	-$30.50M	-$104.5M
Capital Expenditures	$280.0K	$223.0K	$773.0K
Free Cash Flow	-$21.39M	-$30.73M	-$105.2M
YoY Change	-11.03%	52.48%	65.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001840904
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1350
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1654
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	00000
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40493
CY2022	dei	Entity Registrant Name EntityRegistrantName	ATAI Life Sciences N.V.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	P7
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	ATAI Life Sciences N.V.
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Wallstraße 16, 10179
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Berlin
CY2022	dei	Entity Address Country EntityAddressCountry	DE
CY2022	dei	City Area Code CityAreaCode	49 89
CY2022	dei	Local Phone Number LocalPhoneNumber	2153 9035
CY2022	dei	Security12b Title Security12bTitle	Common shares, par value €0.10 per share
CY2022	dei	Trading Symbol TradingSymbol	ATAI
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	411100000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	166010476
CY2022	dei	Auditor Firm AuditorFirmId	34
CY2022	dei	Auditor Name AuditorName	DELOITTE & TOUCHE LLP
CY2022	dei	Auditor Location AuditorLocation	New Jersey
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190613000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	362266000
CY2022Q4	atai	Debt Securities Carried At Fair Value DebtSecuritiesCarriedAtFairValue	82496000
CY2021Q4	atai	Debt Securities Carried At Fair Value DebtSecuritiesCarriedAtFairValue	0
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14036000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11903000
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	913000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	287145000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	375082000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	928000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149000
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	16131000
CY2022Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	6755000
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	11628000
CY2022Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	7262000
CY2021Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	3835000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3351000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7341000
CY2022Q4	us-gaap	Assets Assets	305441000
CY2021Q4	us-gaap	Assets Assets	414166000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2399000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6004000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17306000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14829000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	51000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	192000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	51000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19897000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20935000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	953000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2432000
CY2022Q4	atai	Convertible Promissory Notes Related Parties Transaction ConvertiblePromissoryNotesRelatedPartiesTransaction	415000
CY2021Q4	atai	Convertible Promissory Notes Related Parties Transaction ConvertiblePromissoryNotesRelatedPartiesTransaction	743000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	14702000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	0
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3708000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4097000
CY2022Q4	us-gaap	Liabilities Liabilities	39675000
CY2021Q4	us-gaap	Liabilities Liabilities	28207000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	165935914
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	165935914
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	160677001
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	160677001
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18562000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	18002000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	774092000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	725045000
CY2022Q4	atai	Share Subscription Receivable ShareSubscriptionReceivable	-24000
CY2021Q4	atai	Share Subscription Receivable ShareSubscriptionReceivable	0
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-21702000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8336000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-510188000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-357803000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	260740000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	376908000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	5026000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	265766000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	385959000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	305441000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	414166000
CY2022	us-gaap	Revenues Revenues	233000
CY2021	us-gaap	Revenues Revenues	20376000
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	74313000
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	47956000
CY2022	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	357000
CY2021	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	15480000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	70350000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	92745000
CY2022	us-gaap	Operating Expenses OperatingExpenses	145020000
CY2021	us-gaap	Operating Expenses OperatingExpenses	156181000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-144787000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-135805000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	548000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	205000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1475000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-173000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-41000
CY2022	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-336000
CY2021	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	87000
CY2022	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent	272000
CY2021	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent	0
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
CY2021	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	12346000
CY2022	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	0
CY2021	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	-513000
CY2022	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	4900000
CY2021	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
CY2022	atai	Gain On Deconsolidation Of A Variable Interest Entity GainOnDeconsolidationOfAVariableInterestEntity	1484000
CY2021	atai	Gain On Deconsolidation Of A Variable Interest Entity GainOnDeconsolidationOfAVariableInterestEntity	0
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6902000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	8481000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1412000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-293000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9605000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-796000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-135182000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-136601000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6229000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3989000
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0
CY2021	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-16006000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-58555000
CY2022	us-gaap	Profit Loss ProfitLoss	-157417000
CY2021	us-gaap	Profit Loss ProfitLoss	-174244000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5032000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6436000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-152385000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167808000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.98
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.98
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	155719585
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	155719585
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138265859
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138265859
CY2022	us-gaap	Profit Loss ProfitLoss	-157417000
CY2021	us-gaap	Profit Loss ProfitLoss	-174244000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-13366000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-14155000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-170783000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-188399000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	5032000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	6436000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	50000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-24000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-4982000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-6460000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-165801000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-181939000
CY2020Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	95368000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140868000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7259000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	63362000
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	8411000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	935000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	63362000
CY2021	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-14179000
CY2021	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-171690000
CY2021Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	385959000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4913000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2295000
CY2022	atai	Issuance Of Subsidiary Preferred Shares IssuanceOfSubsidiaryPreferredShares	600000
CY2022	atai	Issuance Of Subsidiary Common Shares IssuanceOfSubsidiaryCommonShares	357000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42375000
CY2022	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-13316000
CY2022	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-157417000
CY2022Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	265766000
CY2022	us-gaap	Profit Loss ProfitLoss	-157417000
CY2021	us-gaap	Profit Loss ProfitLoss	-174244000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	168000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	131000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	195000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1475000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-173000
CY2022	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent	272000
CY2021	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent	0
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5074000
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
CY2021	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-41000
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	852000
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0
CY2022	atai	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	336000
CY2021	atai	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-87000
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
CY2021	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	12346000
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0
CY2021	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
CY2022	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes	0
CY2021	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes	513000
CY2022	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
CY2021	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
CY2022	atai	Gain On Deconsolidation Of A Variable Interest Entity GainOnDeconsolidationOfAVariableInterestEntity	1484000
CY2021	atai	Gain On Deconsolidation Of A Variable Interest Entity GainOnDeconsolidationOfAVariableInterestEntity	0
CY2022	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	16006000
CY2021	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	58555000
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	357000
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	15480000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	42375000
CY2021	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	0
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4636000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	4950000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	11346000
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-161000
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	43000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1522000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9699000
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	5973000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3034000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2300000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1221000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5756000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	12000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-104467000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63246000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	773000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	173000
CY2022	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	251000
CY2021	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	955000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	309058000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	226834000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	47000
CY2022	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	0
CY2021	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	1000000
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	52937000
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	600000
CY2021	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	23658000
CY2022	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	3000000
CY2021	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	2600000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86848000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81276000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	409884000
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	12350000
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	534000
CY2022	us-gaap	Proceeds From Secured Lines Of Credit ProceedsFromSecuredLinesOfCredit	0
CY2021	us-gaap	Proceeds From Secured Lines Of Credit ProceedsFromSecuredLinesOfCredit	2417000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2294000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	935000
CY2022	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	600000
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6854000
CY2022	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	15000000
CY2021	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	0
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1745000
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1588000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20785000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	409862000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1123000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-320000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-171653000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	265020000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	362266000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97246000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190613000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	362266000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	508000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	652000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
CY2022	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	487000
CY2021	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	0
CY2022	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	357000
CY2021	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	0
CY2022	atai	Shares Subscriptions Receivable SharesSubscriptionsReceivable	24000
CY2021	atai	Shares Subscriptions Receivable SharesSubscriptionsReceivable	0
CY2022	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	0
CY2021	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	392000
CY2022	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	0
CY2021	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	2555000
CY2022	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0
CY2021	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	4761000
CY2022	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	0
CY2021	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	646000
CY2022	atai	Exercise Of Hurdle Share Option Plan Award ExerciseOfHurdleShareOptionPlanAward	0
CY2021	atai	Exercise Of Hurdle Share Option Plan Award ExerciseOfHurdleShareOptionPlanAward	527000
CY2022	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes	0
CY2021	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes	3258000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="notes" style="text-indent:0.0%;font-size:10.0pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1. Or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">ganization and Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">ATAI Life Sciences N.V. (“atai”) is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Since inception, atai has either created wholly owned subsidiaries or has made investments in certain controlled entities, including variable interest entities (“VIEs”) for which atai is the primary beneficiary under the VIE model (collectively, the “Company”). atai is headquartered in Berlin, Germany.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has determined that it has one operating and reporting segment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Corporate Reorganization and Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">atai was incorporated pursuant to the laws of the Netherlands as a Dutch private company with limited liability on September 10, 2020 for the purposes of becoming a holding company for ATAI Life Sciences AG and consummating the corporate reorganization described below. atai did not conduct any operations prior to the corporate reorganization other than activities incidental to its formation. ATAI Life Sciences AG was formed as a separate company on February 7, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In contemplation of the consummation of atai’s initial public offering (“IPO”) of common shares, atai undertook a corporate reorganization (the “Corporate Reorganization”). The Corporate Reorganization consisted of several steps as described below:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Exchange of ATAI Life Sciences AG Securities for ATAI Life Sciences B.V. Common Shares and Share Split</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">: In April 2021, the existing shareholders of ATAI Life Sciences AG each became a party to a separate notarial deed of issue under Dutch law and (i) subscribed for new common shares in ATAI Life Sciences B.V. and (ii) transferred their respective shares in ATAI Life Sciences AG, on a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1 to 10 basis</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> (the “Exchange Ratio”), to ATAI Life Sciences B.V. as a contribution in kind on the common shares in ATAI Life Sciences B.V. As a result of the issuance of common shares in ATAI Life Sciences B.V. to the shareholders of ATAI Life Sciences AG and the contribution and transfer of their respective shares in ATAI Life Sciences AG to ATAI Life Sciences B.V., ATAI Life Sciences AG became a wholly owned subsidiary of ATAI Life Sciences B.V. No shareholder rights or preferences changed as a result of the share for share exchange. In connection with such exchange, the common share in ATAI Life Sciences B.V. held by Apeiron was cancelled. On June 7, 2021, shares of ATAI Life Sciences B.V. were split applying a ratio of </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.6 to one</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, and the nominal value of the shares was reduced to €</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, pursuant to a shareholders’ resolution and amendment to the articles of association.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Conversion of ATAI Life Sciences B.V. into ATAI Life Sciences N.V.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">: Immediately preceding the Company’s IPO, the legal form of ATAI Life Sciences B.V. was converted from a Dutch private company with limited liability to a Dutch public company, and the articles of association of ATAI Life Sciences N.V., became effective. Following the Corporate Reorganization, ATAI Life Sciences N.V. became the holding company of ATAI Life Sciences AG.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Corporate Reorganization, as described above, is considered a continuation of ATAI Life Sciences AG resulting in no change in the carrying values of assets or liabilities. As a result, the financial statements for periods prior to the Corporate Reorganization are the financial statements of ATAI Life Sciences AG as the predecessor to atai for accounting and reporting purposes. All share, per-share and related information presented in these consolidated financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the share exchange and share split resulting from the Corporate Reorganization. In connection with the Corporate Reorganization, outstanding share awards and option grants of ATAI Life Sciences AG were exchanged for share awards and option grants of ATAI Life Sciences B.V. with identical restrictions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On June 22, 2021, atai closed the IPO of its common shares on the Nasdaq Stock Market ("Nasdaq"). As part of the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of its common shares, which included </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">231.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million from the IPO, after deducting underwriters’ discounts and commissions of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million and offering costs of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Impact of COVID-19 Pandemic</span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The COVID-19 pandemic has continued to present global public health and economic challenges during the year ended December 31, 2022. The Company has not experienced material financial impacts on its business and operations. The Company continues to monitor the impact of the COVID-19 pandemic on its employees and business and has undertaken business continuity measures to mitigate potential disruption to its operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The future impact of COVID-19 on the Company’s business and operations, including its research and development programs and related clinical trials, will largely depend on future developments, which are highly uncertain, such as the duration of the pandemic, the spread of the disease and variants thereof, the availability and effectiveness of vaccines and related roll-out efforts, breakthrough infections among the vaccinated, vaccine hesitancy, the implementation of vaccine mandates, travel restrictions, social distancing and related government actions around the world, business closures or business disruptions and the ultimate impact of COVID-19 on financial markets and the global economy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">190.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, short-term securities of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">82.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million and its accumulated deficit was $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">510.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million. The Company has historically financed its operations through the sale of equity securities, debt financings, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents and short-term securities as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the consolidated financial statements are issued.</span></p>
CY2021	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1 to 10 basis
CY2021Q2	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1.6 to one
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190600000
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	82500000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-510200000
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2022Q4	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	6800000
CY2022Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	7200000
CY2021Q4	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	11600000
CY2022Q4	atai	Noncontrolling Interest Ownership Percentage NoncontrollingInterestOwnershipPercentage	1
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to the fair value of the Company’s investment in Intelgenx Technologies Corp. (“IntelGenx”), securities carried at fair value, contingent consideration liability—related parties, in-process research and development (“IPRD”) assets, derivative liability associated with the Perception convertible promissory notes, redeemable noncontrolling interests and noncontrolling interests recognized in acquisitions, the valuations of common shares prior to IPO and share-based awards, and accruals for research and development costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Additionally, the Company assessed the impact that the COVID-19 pandemic has had on its operations and financial results as of December 31, 2022 and through the issuance of these consolidated financial statements. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. The Company has not experienced any significant financial impacts due to COVID-19.</span></p>
CY2022	atai	Risks And Uncertainties RisksAndUncertainties	<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is subject to risks common to companies in the biopharmaceutical industry. The Company believes that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations and manufacturers upon which the Company relies; protection of the Company’s intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company’s ability to attract and retain employees.</span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and all no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">tes receivables. The Company’s cash is mainly held in financial institutions in the United States, United Kingdom, Germany and Australia. Amounts on deposit may at times exceed federally insured limits. The credit risk associated with the Company’s investment in all notes receivables is monitored and assessed periodically. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments.</span></p>
CY2021Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	3800000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	154830000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
CY2022	atai	Impairment Loss Recognized ImpairmentLossRecognized	0
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	0
CY2021Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	0
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	16131000
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.69
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.56
CY2020Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	77200000
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	100000
CY2021Q1	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	100000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	500000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2200000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	4546000
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	8411000
CY2021	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	-5153000
CY2021	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	1271000
CY2021	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-24000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2022	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	957000
CY2022	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-4675000
CY2022	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	-357000
CY2022	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	50000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	5026000
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021	atai	Issuance Of Redeemable Noncontrolling Interests IssuanceOfRedeemableNoncontrollingInterests	2555000
CY2021	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	-2555000
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	32200000
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	152200000
CY2022Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	6755000
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	11628000
CY2022	atai	Equity Method Investment Shares Transaction Date EquityMethodInvestmentSharesTransactionDate	2026-12-31
CY2022	us-gaap	Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions	9600000
CY2022	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2400000
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
CY2022Q4	atai	Term Loan Impairment Loss Recognized TermLoanImpairmentLossRecognized	0
CY2022Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000
CY2021Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000
CY2022Q4	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.050
CY2021Q4	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.050
CY2022Q4	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	4626000
CY2021Q4	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	2692000
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	5631000
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	5406000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2034000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3049000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1745000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	756000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14036000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11903000
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	15000000
CY2022Q4	atai	End Of The Term Charge EndOfTheTermCharge	1042000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-274000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-113000
CY2022Q4	atai	Unamortized End Of Term Charge UnamortizedEndOfTermCharge	-952000
CY2022Q4	us-gaap	Certain Loans Acquired In Transfer Accounted For As Debt Securities Carrying Amount Net CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesCarryingAmountNet	14702000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3566000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2667000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2224000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	8137000
CY2022Q4	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	5550000
CY2021Q4	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	861000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5260000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2832000
CY2022Q4	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	0
CY2021Q4	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	169000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	706000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	163000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17306000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14829000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-5000
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	415000
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	743000
CY2022Q4	us-gaap	Loans Held For Sale Maturity Date LoansHeldForSaleMaturityDate	2026-08-01
CY2022	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	175000000.0
CY2022Q4	atai	Prime Rate Percent PrimeRatePercent	0.0455
CY2022Q4	atai	Accrued Interest Payable AccruedInterestPayable	0.0855
CY2022Q3	atai	Borrowing Amount Percentage BorrowingAmountPercentage	0.33
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	14702000
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4900000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18873715
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7300000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-55845000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-89061000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-79337000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-47540000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-135182000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-136601000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1155000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1117000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1155000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1117000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	5074000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-5106000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5074000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5106000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6229000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3989000
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-135182000
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-136601000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3018
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3018
CY2022	atai	Income Tax Reconciliation Expected Income Tax Expense Benefit IncomeTaxReconciliationExpectedIncomeTaxExpenseBenefit	-40791000
CY2021	atai	Income Tax Reconciliation Expected Income Tax Expense Benefit IncomeTaxReconciliationExpectedIncomeTaxExpenseBenefit	-41220000
CY2022	atai	Income Tax Reconciliation State Income Taxes Net Of Federal Tax Benefit And Valuation Allowance IncomeTaxReconciliationStateIncomeTaxesNetOfFederalTaxBenefitAndValuationAllowance	-6509000
CY2021	atai	Income Tax Reconciliation State Income Taxes Net Of Federal Tax Benefit And Valuation Allowance IncomeTaxReconciliationStateIncomeTaxesNetOfFederalTaxBenefitAndValuationAllowance	132000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	7276000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4222000
CY2022	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Consolidated Subsidiaries Regarding Ipr D Charges And Acquisition Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInConsolidatedSubsidiariesRegardingIprDChargesAndAcquisitionAdjustments	0
CY2021	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Consolidated Subsidiaries Regarding Ipr D Charges And Acquisition Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInConsolidatedSubsidiariesRegardingIprDChargesAndAcquisitionAdjustments	3251000
CY2022	atai	Effect Of Australian Rd Tax Credit Incentives EffectOfAustralianRDTaxCreditIncentives	-338000
CY2021	atai	Effect Of Australian Rd Tax Credit Incentives EffectOfAustralianRDTaxCreditIncentives	-3000
CY2022	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Consolidated Subsidiaries Regarding Fair Value Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInConsolidatedSubsidiariesRegardingFairValueAdjustments	-109000
CY2021	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Consolidated Subsidiaries Regarding Fair Value Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInConsolidatedSubsidiariesRegardingFairValueAdjustments	2934000
CY2022	atai	Effect Of Consolidation And Deconsolidation Of Subsidiaries EffectOfConsolidationAndDeconsolidationOfSubsidiaries	-1394000
CY2021	atai	Effect Of Consolidation And Deconsolidation Of Subsidiaries EffectOfConsolidationAndDeconsolidationOfSubsidiaries	0
CY2022	atai	Effect Of Statutory Accounting Adjustments EffectOfStatutoryAccountingAdjustments	98000
CY2021	atai	Effect Of Statutory Accounting Adjustments EffectOfStatutoryAccountingAdjustments	-10409000
CY2022	atai	Compensation Expenses Not Deductible Under Irc Sections CompensationExpensesNotDeductibleUnderIrcSections	411000
CY2021	atai	Compensation Expenses Not Deductible Under Irc Sections CompensationExpensesNotDeductibleUnderIrcSections	1690000
CY2022	atai	Expenses Not Deductible For Tax Purposes ExpensesNotDeductibleForTaxPurposes	-324000
CY2021	atai	Expenses Not Deductible For Tax Purposes ExpensesNotDeductibleForTaxPurposes	612000
CY2022	atai	Effect Of Share Based Compensation Expense EffectOfShareBasedCompensationExpense	216000
CY2021	atai	Effect Of Share Based Compensation Expense EffectOfShareBasedCompensationExpense	192000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	758000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	657000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	46935000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	35267000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6229000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3989000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0461
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0292
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	66000
CY2022Q4	atai	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	31078000
CY2021Q4	atai	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	17231000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	11975000
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	0
CY2022Q4	atai	Deferred Tax Assets Other Deductible Timing Differences DeferredTaxAssetsOtherDeductibleTimingDifferences	1864000
CY2021Q4	atai	Deferred Tax Assets Other Deductible Timing Differences DeferredTaxAssetsOtherDeductibleTimingDifferences	829000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	101062000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57893000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	95678000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49442000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5384000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8451000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	908000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	17000
CY2022Q4	atai	Deferred Tax Liabilities Unrealised Foreign Exchange DeferredTaxLiabilitiesUnrealisedForeignExchange	-4472000
CY2021Q4	atai	Deferred Tax Liabilities Unrealised Foreign Exchange DeferredTaxLiabilitiesUnrealisedForeignExchange	-3326000
CY2022Q4	atai	Deferred Tax Liabilities Outside Basis Differences In Equity And Other Investments DeferredTaxLiabilitiesOutsideBasisDifferencesInEquityAndOtherInvestments	-4000
CY2021Q4	atai	Deferred Tax Liabilities Outside Basis Differences In Equity And Other Investments DeferredTaxLiabilitiesOutsideBasisDifferencesInEquityAndOtherInvestments	-2000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5384000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3345000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	5106000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	95700000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49400000
CY2022Q4	atai	Unremitted Earnings UnremittedEarnings	0
CY2021Q4	atai	Unremitted Earnings UnremittedEarnings	0
CY2022	atai	Federal Tax Loss Carryforward FederalTaxLossCarryforward	150991000
CY2021	atai	Federal Tax Loss Carryforward FederalTaxLossCarryforward	103232000
CY2022	atai	Overseas Tax Loss Carryforward OverseasTaxLossCarryforward	41908000
CY2021	atai	Overseas Tax Loss Carryforward OverseasTaxLossCarryforward	31875000
CY2022	atai	Tax Loss Carryforward TaxLossCarryforward	192899000
CY2021	atai	Tax Loss Carryforward TaxLossCarryforward	135107000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022	us-gaap	Profit Loss ProfitLoss	-157417000
CY2021	us-gaap	Profit Loss ProfitLoss	-174244000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5032000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6436000
CY2022	atai	Net Income Attributable To Common Stockholders Basic And Diluted NetIncomeAttributableToCommonStockholdersBasicAndDiluted	-152385000
CY2021	atai	Net Income Attributable To Common Stockholders Basic And Diluted NetIncomeAttributableToCommonStockholdersBasicAndDiluted	-167808000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	155719585
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	155719585
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138265859
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138265859
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.98
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.98
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	48004257
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	44388892
CY2022	us-gaap	Lease Cost LeaseCost	1800000
CY2020Q3	atai	Related Party Reservation Rate Of Common Shares For Ipo RelatedPartyReservationRateOfCommonSharesForIpo	0.27
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	500000

Files In Submission

Name	View Source	Status
atai-20221231_def.xml	Edgar Link	unprocessable
0000950170-23-009756-index-headers.html	Edgar Link	pending
0000950170-23-009756-index.html	Edgar Link	pending
0000950170-23-009756.txt	Edgar Link	pending
0000950170-23-009756-xbrl.zip	Edgar Link	pending
atai-20221231.htm	Edgar Link	pending
atai-20221231.xsd	Edgar Link	pending
atai-ex10_27.htm	Edgar Link	pending
atai-ex10_28.htm	Edgar Link	pending
atai-ex10_29.htm	Edgar Link	pending
atai-ex10_30.htm	Edgar Link	pending
atai-ex21_1.htm	Edgar Link	pending
atai-ex23_1.htm	Edgar Link	pending
atai-ex23_2.htm	Edgar Link	pending
atai-ex31_1.htm	Edgar Link	pending
atai-ex31_2.htm	Edgar Link	pending
atai-ex32_1.htm	Edgar Link	pending
atai-ex32_2.htm	Edgar Link	pending
atai-ex4_2.htm	Edgar Link	pending
atai-ex99_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img105044015_0.jpg	Edgar Link	pending
img105044015_1.jpg	Edgar Link	pending
img105044015_2.jpg	Edgar Link	pending
img105044015_3.jpg	Edgar Link	pending
img105044015_4.jpg	Edgar Link	pending
img105044015_5.jpg	Edgar Link	pending
img105044015_6.jpg	Edgar Link	pending
img105044015_7.jpg	Edgar Link	pending
img105044015_8.jpg	Edgar Link	pending
img105044015_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
atai-20221231_cal.xml	Edgar Link	unprocessable
atai-20221231_lab.xml	Edgar Link	unprocessable
atai-20221231_pre.xml	Edgar Link	unprocessable
atai-20221231_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATAI
ATAI Life Sciences NV Stock $atai

2023 Q1 Form 10-K Financial Statement

#000095017023009756 Filed on March 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI ATAI Life Sciences NV Stock $atai

2023 Q1 Form 10-K Financial Statement

#000095017023009756 Filed on March 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI
ATAI Life Sciences NV Stock $atai